Furthermore, AML patients with low expression of TXNIP, NLRP3 and CASP1 and low expression of TXNIP, NLRP3 and IL1B were significantly associated with favorable OS (1-year OS: TXNIPlowNLRP3lowCASP1low vs. TXNIPhighNLRP3highCASP1high vs. TXNIPhigh or NLRP3high or CASP1high, 86% vs 56% vs 44%, P = 0.001; TXNIPlowNLRP3lowIL1Blow vs. TXNIPhighNLRP3highIL1Bhigh vs. TXNIPhigh or NLRP3high or IL1Bhigh, 81% vs 45% vs 54%, P = 0.050, Figure 3B, C). This evidence concerns the gene NLRP3 and acute myeloid leukemia.